Site logo
Pharmaville Logo
    • Featured
    • Cornerstone Life Science Locations
    • Home
    • Locations
    • Events
    • Articles
      • Featured Editorial & Interviews
      • News and Insights
      • Xtalks Clinical Edge Magazine
    • More
      • Add or Update a Listing
      • About Pharmaville
      • Visit Xtalks
      • Contact
      • Terms of Use
      • Privacy Notice
    Add or Enhance a Listing
    Sign in or Register
    Add or Enhance a Listing
    Listing cover image

    Clinical Trials in Australia: Recommendations for Maximizing Collaboration between China and Australia

    🖥️ Live Webinar

    • Event date
      May 13, 2024 - May 13, 2024
    • Webinar Details
    • prev
    • next
    • Bookmark
    • Share
    • Register
    • prev
    • next
    Description

    China’s rapid growth in clinical trials and biotechnology has been a focal point of the global industry. Understanding this ecosystem’s latest trends and evolution is essential for companies looking to expand their operations or collaborate with partners in China. Similarly, Australia’s regulatory environment plays a crucial role in the success of clinical trials conducted in the country.

    The collaboration between China and Australia holds immense potential for clinical trial and biotech industries. This webinar explores the current landscape of clinical trials and the biotech ecosystem in China and sheds light on trends and evolutionary patterns. Participants will gain insights into strategies for more effective partnerships between Chinese and Australian companies.

    Moreover, the webinar will highlight how dynamics between sites, investigators and recruitment strategies vary across different therapy areas. Understanding these nuances is crucial for optimizing clinical trial outcomes. Through expert insights and case studies, attendees will learn practical recommendations and best practices for maximizing collaboration and ensuring successful clinical trials in Australia.

    This webinar will also provide attendees with a good overview of the regulatory pathway in Australia, including key considerations for data governance, technology adoption and stakeholder engagement.

    Overall, this webinar offers industry professionals a valuable opportunity to gain insights into the clinical trial landscapes in China and Australia and discover practical strategies for maximizing collaboration and ensuring successful outcomes. This includes identifying common areas of interest, leveraging each other’s strengths and navigating potential challenges. The discussion will also cover the importance of cultural understanding and effective communication in cross-border collaborations.

    Register for this webinar today to gain insights into conducting clinical trials in Australia and discover practical strategies for maximizing collaboration between China and Australia.

    What You Will Learn

    Attendees will learn about:

    - How does the clinical trials and biotech ecosystem look like in China today
    - How can Chinese and Australian companies partner more effectively
    - Regulatory pathway in Australia: data governance, technology and stakeholders
    - How dynamics between sites, investigators and recruitment change depending on the therapy area

    Who Should Attend

    This webinar will appeal to C-Suite executives and professionals in biotech, pharma and CROs working within:

    - Clinical innovation and strategy
    - Clinical development and market access
    - Business development and partnerships
    - Cross-border — China and Australia

    Speaker(s)
    (Moderator) Tam Nguyen, Deputy Director of Research, St. Vincent’s Hospital Melbourne

    Associate Professor Tam Nguyen has close to 25 years of experience of working in clinical trials, health and medical research and the research management sector, including tertiary teaching hospitals, medical research institutes and universities across Australia.

    Tam is the Deputy Director of Research at St. Vincent’s Hospital Melbourne and is responsible for research strategy, research development and innovation. Tam serves as a Non-Executive Director and Advisor to several MedTech and HealthTech start-ups and scale-ups.

    He’s a co-editor of a recent book: AI in Medicine (Springer) and is regularly invited to speak on a broad range of topics such as clinical trials, innovation, industry collaboration, digital health and AI and machine learning in health. He chairs, moderates and serves on program committees at numerous national and international conferences.

    Dr. Robert Lin, CEO, GreenLight Clinical

    Dr. Robert Lin is the CEO of Greenlight Clinical. He is a highly qualified healthcare executive with over 20 years of clinical and managerial experience.

    As a healthcare professional who is passionate about advancing medical facilities, treatments and patient-centric care, Dr. Lin has extensive experience in managing private, public and international hospitals and other facilities. His expertise in this area spans strategic planning, improving operational efficiency, team building and project management.

    With a commitment to sharing his knowledge and skills to enhance healthcare in the community, Dr. Lin has been the Chairman of the NSW Radiation Therapist Research Group and the Clinical Specialist Director of the Australian Medical Radiation Sciences Accreditation Council. He also served as a member of the expert panel of the Trans-Tasman Radiation Oncology Group and the lung cancer reference group for Cancer Australia.
    Dr. Lin’s professional insights are widely published, and he is a reviewer and invited author of the Journal of Medical Radiation Sciences.

    As someone who drives positive development in the healthcare industry, Dr. Lin believes that optimal outcomes and improved patient experiences are best achieved through understanding difficult concepts, turning ideas into logical strategies and implementing appropriate systems.

    Nate Zhang, VP, GM Overseas Business, Taimei Technology

    Nate Zhang is a global leader and pioneer of digital health and digital transformation, currently leading Taimei Technology’s international business expansion. He has more than 15 years of experience in enterprise software and healthcare industries across three continents (Asia, North America and Europe) covering both developed and developing markets.

    Prior to Taimei, Nate was the Founder of Alibaba Cloud’s digital health ecosystem and was leading the digital health solutions and Global-ISV solutions of Alibaba Cloud.

    He is also the Founder of Medtronic’s digital health team and Founder of Medtronic XR Lab. During this period, Nate and his team invented the remote self-service follow-up machine for pacemaker patients in China, followed by successful commercialization through the Shanghai International Import Expo. Nate and his team also developed China’s first AR-based surgical training and guidance system of percutaneous coronary intervention for bifurcation lesions “AR Bifur,” which benefits thousands of physicians in China. Nate was also one of the early core members of Veeva Systems in China.

    Lisa Nelson, CEO, Scientia Clinical Research

    Lisa Nelson has 30 years of clinical trial experience with extensive Phase I experience, both local and international, including the design, establishment and running of Scientia Clinical Research, Nucleus Network and Linear Clinical Research. A leader in her field, Lisa is the CEO of Scientia Clinical Research: the first purpose-built, early-phase clinical trial facility in NSW. Integral to this success is Lisa’s knowledge and experience in setting up and managing globally recognised Phase I units in other states, creating new business opportunities, developing key client relationships and keeping abreast of developments in early-phase drug and device research. The US and China are her prime focus. Lisa has very broad and insightful perspective on what is happening in the pharmaceutical and biotechnology world today.

    Dr. Hui Zhou, SVP, Clinical Development for New Drugs, Innovent Biologics

    Dr. Hui Zhou, MD, is SVP of Clinical Development for New Drugs. In January 2016, Dr. Hui joined Innovent and was responsible for and leading the clinical development, registration and marketing of several tumor products, including Sintilimad. Currently, Dr. Hui is responsible for clinical development, research design and executive management of new drugs in the oncology field.

    He has worked in clinical development or medical affairs in the medical or R&D departments of Astrazeneca, Amgen and Roche. Before joining the pharmaceutical industry, he worked at Zhongshan Hospital, which is affiliated to Fudan University. He is also a member of the following committees: Clinical Research Committee of China Anti-Cancer Association; the Clinical Research Committee of Chinese Society of Clinical Oncology; Translational Medicine Committee, Chinese Society of Clinical Oncology; and Clinical Trial Committee, China Pharmaceutical Innovation Promotion Association.

    Register for this Event
    Register Now
    Upcoming Dates
    • May 13, 2024 12:00 am - 12:00 am Ended
    Hosted By

    Xtalks Pharmaville

    Categories
    • Virtual Event
    Location
    • Canberra, District of Canberra Central, Australian Capital Territory, 2600, Australia

      Get Directions
    Region
    • Australia

    You May Also Be Interested In

    Critical Elements of Conducting Early Phase Clinical Trials in the US for APAC Sponsors

    • May 12, 2022 12:00 am - 12:00 am

    A Guide to Preclinical and CMC Requirements for Conducting Clinical Trials in Australia

    • Canberra
    • April 28, 2022 12:00 am - 12:00 am
    Australia
    • Quick view
    • Bookmark

    Clinical Research in LATAM: From a Standalone Site to a Regional Network

    • September 26, 2025 12:00 am - 12:00 am
    • Terms of Use
    • Privacy Notice

    © Honeycomb Worldwide Inc.

    Cart

      • Featured
      • Cornerstone Life Science Locations
      • Facebook
      • LinkedIn